Navigation Links
Omeros Announces Publication of Data From Antifibrinolytic Program
Date:2/10/2011

rol of blood loss during surgery or resulting from trauma. Omeros' agents are designed to selectively inhibit plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of kallikrein and Factor XIa, important enzymes in the coagulation cascade. These agents could provide a superior replacement for the antifibrinolytic agents Trasylol® (aprotinin), tranexamic acid and epsilon aminocaproic acid.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include the ability of Omeros' antifibrinolytic agents to provide more effective bleeding control with fewer side effe
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Licenses Novel Antifibrinolytic Agents
2. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
3. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
4. Omeros to Present at the BioCentury NewsMakers Conference
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. Omeros Successfully Unlocks Orphan GPCRs
7. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
8. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
9. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
10. Daniel K. Spiegelman Elected to Board of Directors of Omeros
11. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: North ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North America ... GlobalData,s new report, "North America Laparoscopes Market Outlook ... North America Laparoscopes market. The report provides value, ...
(Date:8/28/2014)... , Aug. 28, 2014 Pharmatech ... two-year investment into this game-changing method for matching ... Today, clinical trials target specific cancers, disease ... contributing factors for the cancer, in the first ... that this information may not be well known ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- EDGE Orthopaedics, ... space, is excited to announce they have received ... Plating System and REDUCE Fracture Plating System. ... used to support multiple indications within the mid-foot. ... First Metatarsophalangeal (MTP), Calcaneal-Cuboid (CC), Talonavicular (TN) and ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2EDGE Orthopaedics Receives Second FDA Clearance 2
... Kluwer Pharma Solutions, Inc., a leading provider of scientific information ... that Rep. Ben Quayle ( R-AZ, 3 ... analytics management team to discuss the company,s role in the ... company,s offices on Camelback Road in Phoenix to learn more ...
... WORTH, Texas, Aug. 24, 2011 The UNT System Board ... authorized in the 82nd Texas legislative session. As part of ... and UNT Dallas, the College of Pharmacy students will earn ... graduate portion of their classes on the UNT Health Science ...
Cached Medicine Technology:Congressman Quayle Talks With Wolters Kluwer Pharma Solutions About Importance of Health Information 2Congressman Quayle Talks With Wolters Kluwer Pharma Solutions About Importance of Health Information 3UNT Regents Approve New College of Pharmacy 2
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 Hope ... of this fall’s Spouse/Caregiver Scholarships. Scholarships are awarded two ... service members or to spouses of fallen service members. ... to restoring a sense of self, restoring the family ... our military families. , The Spouse/Caregiver Scholarship Program ...
(Date:8/29/2014)... August 29, 2014 First Choice Emergency ... at 7am today. The new facility is located 1501 FM ... team is pleased to be a part of First Choice ... to continuing to deliver high quality emergency medical care to ... of First Choice Emergency Room Pflugerville – FM 685. ...
(Date:8/29/2014)... August 29, 2014 Most dentists work during ... find a break in their day to be able to ... business professionals to find a few hours during their increasingly ... York Dental so important. It is now possible for people ... need. , What is happening? , North York Dental has ...
(Date:8/29/2014)... 2014 http://www.fdanews.com/CTMPR , FDAnews ... Magnifier Weekly. , Clinical Trial Magnifier Weekly monitors 150,000 ... and reports all the fresh changes. By sifting through ... extract just the information readers need. Subscribers are able ... links in the newsletter to focus on the ones ...
(Date:8/29/2014)... 29, 2014 Canadian Healthy Vending ... recently completed its annual survey of its 200 operators ... of the products that appeal to Canadian consumer seeking ... to list their top five selling healthy snacks and ... an increasingly important issue for consumers, employers, and families. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Fall 2014 Spouse/Caregiver Scholarship Recipients 2Health News:Hope For The Warriors Announces Fall 2014 Spouse/Caregiver Scholarship Recipients 3Health News:First Choice Emergency Room Opens New Facility in Pflugerville, Texas 2Health News:North York Dental Provides Dental Services to Busy Professionals 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 3Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 4Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 3
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... and urethral pressure profilometry. Dual ... to be filled while cystometry ... catheter design enhances visualization during ... in peel-open packages. Intended for ...
... Scientifics SAFE-T-FILL Capillary Blood Collection Tubes are ... for a wide range of applications, the ... capillary tube, attached cap and a micro ... draw the blood into the micro tube ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection ... systems. Available for a wide range of ... with a capillary tube, attached cap and ... action to draw the blood into the ...
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection Tubes ... Available for a wide range of applications, ... a capillary tube, attached cap and a ... to draw the blood into the micro ...
Medicine Products: